Biological Evaluation Report (BER) Review Service
Independent review of an existing ISO 10993 Biological Evaluation Report for teams that already have a draft, but need to know whether the endpoint conclusions, waiver rationale, chemistry use, and reviewer-facing logic are actually defensible.
Key review strengths
2-4 Day Review Window
Built for pre-submission checks, urgent internal reviews, and teams that need a faster answer before they rewrite the report.
Written Findings Memo
Specific comments on where the BER is strong, generic, under-argued, or likely to trigger reviewer follow-up.
Endpoint Conclusion Check
Focus on whether each biological endpoint is actually concluded with enough device-specific reasoning and evidence support.
Chemistry and File Alignment
Tests whether chemistry, TRA, risk management, and technical-file language are helping the BER instead of sitting beside it.
Best for teams that already have a BER draft but do not want to discover structural weaknesses during review
This is not the right service when you need a new BER written from nothing. It is the right service when a report already exists, but the team needs an ISO 10993 specialist to test whether the finished-device framing, endpoint conclusions, waiver logic, and chemistry integration are strong enough for a reviewer-facing file.
The current BER feels too generic
The report looks complete at first glance, but the conclusions still read like summary statements instead of real scientific evaluation.
You want a pre-submission check
The BER is nearly ready, but you want an outside review before it goes to FDA, a notified body, or an internal quality gate.
The device or evidence changed after the first draft
Supplier, coating, sterilization, chemistry, or device-description changes may have weakened the report more than the team realizes.
Your team drafted it internally
The first draft exists, but the team wants a specialist check on whether the endpoint conclusions and waiver treatment will survive reviewer scrutiny.
What a strong BER review actually tests
The goal is not to proofread the report. The goal is to determine whether the scientific logic is strong enough to support a reviewer-facing biological safety conclusion.
Finished-Device Framing
Checks whether the report clearly describes the real patient-contacting device state, including materials, additives, coatings, packaging, and sterilization context.
Evidence Appraisal
Tests whether literature, prior testing, chemistry, and equivalence claims are being evaluated critically instead of simply listed.
Endpoint Conclusion Logic
Reviews whether each endpoint is actually concluded with device-specific reasoning and whether the report is clear about strengths, limits, and residual uncertainty.
Waiver Strategy
Identifies whether waived tests are really supported by existing data, chemistry, literature, or prior evidence, and where the current argument still looks asserted rather than defended.
Chemistry and TRA Integration
Checks whether characterization and toxicology outputs are meaningfully connected back into the biological safety conclusion.
Risk and File Alignment
Assesses whether the BER is structurally aligned with the BEP, ISO 14971 logic, technical-file language, and broader submission narrative.
Situations where BER review usually prevents more expensive rework later
These are the recurring patterns where a specialist review of the report is faster and cheaper than continuing to build a submission around a weak BER.
The report repeats data without evaluating it
The draft summarizes testing and literature, but does not translate that evidence into a clear endpoint-by-endpoint scientific conclusion.
Conclusions sound confident but look under-argued
The endpoint language is directionally reasonable, but the reasoning is not yet explicit enough for external review.
Chemistry exists but is not helping
Characterization or TRA outputs are present, but the BER never closes the logic loop to the biological safety conclusion.
The BER was drafted before the device stabilized
Later changes in materials, coating, packaging, sterilization, or manufacturing often leave the report partly outdated even if nobody notices it immediately.
The team wants to avoid reviewer questions, not answer them later
A pre-submission review is often the cleanest moment to catch avoidable logic gaps before they multiply into FDA or notified body comments.
The current draft may still be repairable
Many BERs do not need a full rewrite; they need targeted repair to evidence appraisal, endpoint reasoning, and chemistry integration.
How the review is usually structured
The work is intentionally narrow: review the current report, isolate the real weaknesses, and decide the smallest sensible next step.
Send the Current Draft
Usually this means the BER, a short device description, known materials, relevant evidence, pathway, and any active timing pressure.
Check the Core Conclusion Logic
The review focuses on endpoint treatment, waived tests, evidence appraisal, chemistry integration, and whether the report truly reflects the finished device.
Deliver the Findings Memo
You receive prioritized comments on what is working, what is weak, and what should be fixed first.
Choose the Next Move
From there the next step is usually targeted revision, a broader review, or a fresh BER drafting engagement if the draft is too generic to repair efficiently.
How BER review is usually packaged
This is usually scoped as a focused fixed-fee review, not open-ended consulting time. Final scope depends on draft quality, file context, and urgency.
Best use of this service: when you already have a BER draft and need a high-value specialist check before committing more revision time or submitting it into a reviewer-facing file.
Single BER draft
Best when you want an expert review of one existing report without expanding into the whole file set yet.
- Written findings memo
- Priority fixes and next-step recommendation
- Follow-up review call
Report review with supporting file context
Best when the draft BER depends on linked chemistry, TRA, BEP, or reviewer comments that affect the conclusion logic.
- Cross-file consistency comments
- Stronger view on waiver viability and evidence sufficiency
- Repair-versus-redraft recommendation
Fast triage under timeline pressure
Best when the BER needs a rapid specialist check before filing, management review, or an active reviewer interaction.
- Fast-turn review of the report logic
- Top issues surfaced first
- Escalation path if broader file work is needed
What usually changes scope
The main drivers are BER maturity, whether chemistry or toxicology context needs checking, how much of the report is still generic, and whether a wider file-alignment issue is already visible.
Need broader document triage instead?
Use the submission gap review when the real concern is not only the BER, but the linked BEP, TRA, or response package as well.
Questions teams usually ask before booking a BER review
Is this for a new BER or an existing one?
This page is for review of an existing BER draft. If you need a new document prepared from scratch, use the BER drafting service.
Can this help if the BER is only partially drafted?
Yes, as long as there is enough content to assess the conclusion logic, evidence treatment, and current waiver approach. If there is almost no structure yet, drafting may be the better fit.
Will the review tell us whether the draft is usable?
Yes. One of the main outputs is a clear judgment on whether the BER is basically sound, needs targeted repair, or is too generic to keep building on.
What if the report is already under reviewer pressure?
If there is already an active FDA or notified body comment set, the more useful path may be the BER remediation page or the wider submission gap review.
Need an expert check on the current BER before you build the rest of the submission around it?
Send the current report, device type, pathway, and timing pressure. I will review the situation and confirm whether a focused BER review is the right first step.